Plus Therapeutics (PSTV) Business update summary

Financial Update and Capital Position

• Completed an oversubscribed $15 million offering, extending runway through 2027 and enabling growth initiatives.

• Access to three ongoing grants supports clinical milestones and operations through 2027.

• Current cash and grants are expected to fund all planned milestones, with CNSIDE business targeting break-even by 2027, though clinical programs will continue to use cash.

• No immediate plans for a reverse stock split; focus remains on execution and generating positive catalysts.

Market Opportunity and Unmet Needs

• Over 1 million U.S. patients are at risk of CNS metastases, with up to 30% of adult cancer patients developing CNS mets, representing a significant and growing market.

• CNSide diagnostic platform targets a $6B U.S. market, with a projected 500,000 patients per year and a commercial relaunch planned for Q3 2025.

• REYOBIQ radiotherapeutic addresses a $16B U.S. market, offering up to 20x radiation delivery versus standard of care and benefiting from FDA Fast Track and Orphan Designations.

Diagnostic and Therapeutic Innovation

• CNSide offers a comprehensive, highly sensitive tumor cell capture and interrogation system, with 95% specificity and 92% sensitivity, and over 11,000 tests completed.

• The platform provides four tests from a single sample, enabling diagnosis, treatment monitoring, and personalized therapy selection.

• REYOBIQ is a first-in-class targeted radiotherapeutic with dual delivery modalities, capable of delivering up to 20x the radiation dose of standard care directly to CNS tumors.

• CNSide Diagnostics offers proprietary CSF assays to improve management of leptomeningeal metastases.